@FierceMedDev: ICYMI yesterday: Activist investor intensifies pressure on Volcano. Article | Follow @FierceMedDev
@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. FierceDrugDelivery story | Follow @MichaelGFierce
@VarunSaxena2: Interesting tidbit about off-label use: biliary stents have been used for cardiac indications in the past, panelists say. | Follow @VarunSaxena2
@EmilyWFierce: Closed-loop epidural stimulation system helped paralyzed rats take 1,000 steps and navigate "rodent-sized stairs." More from MIT Technology Review | Follow @EmilyWFierce
> Google Glass-affiliate Pristine, which develops HIPAA-compliant video streaming, raised $5.4 million in a Series A financing to use towards expansion of its R&D, sales, marketing, and operations teams. Release
> Acutus Medical, developers of the minimally invasive real-time 3D Cardiac Chamber Imaging and Dipole Density Mapping system, raised an additional $26.2 million in Series B financing. Release
> DARPA called for research proposals that offer innovative designs for a portable unit able to generate both neutrons and X-rays in order to maximize the imaging sources and enable more detailed radiography in field settings. Release
> Cohealo, a software development company aimed at helping hospitals manage shared medical device inventory, raised $3.1 million toward its $5.8 million debt financing goal. Story
Biotech News
@FierceBiotech: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here | Follow @FierceBiotech
@JohnCFierce: Baxter inks a big lease in the heart of Cambridge for biopharma R&D headquarters - (more for hubs, less for Chicago). Article | Follow @JohnCFierce
@DamianFierce: $JNJ buying antiviral outfit Alios for $1.75B in cash(!). Press release | Follow @DamianFierce
@EmilyMFierce: New class of antibiotics could fight drug-resistant tuberculosis. FierceBiotech Research story | Follow @EmilyMFierce
> Takeda steps up with $1.6B package of milestones in MacroGenics R&D pact. More
> Regeneron's would-be blockbuster completes the allergic circle with Phase II success. Article
> J&J makes a splash in hep C with a $1.75B deal for Alios. News
Pharma News
@FiercePharma: ICYMI: This week's issue of FierceAnimalHealth. Subscribe here to get it every week. | Follow @FiercePharma
@TracyStaton: ICYMI yesterday: Bristol-Myers' oncology star lines up for lung cancer approval, leading the PD-1 pack. Story from FierceBiotech | Follow @TracyStaton
@CarlyHFierce: Once-rejected drugs in Gilead's Stribild get FDA nod to go it alone. Story | Follow @CarlyHFierce
> Salix's Relistor has its chance to get a jump on AZ's new constipation med. Report
> Allergan's next tug-of-war move: Attack Valeant's rosy Q3 forecast. Story
> AbbVie to employees: We're definitely merging with Shire, new tax rules aside. More
Biotech Research News
> New class of antibiotics could fight drug-resistant tuberculosis. More
> Protein 'map' points way to combating chemo-resistant cancer. Report
> Scientists replicate ALS dementia in mice. Item
> Hemispherx to test FDA-rejected drug, other candidates against Ebola. Article
> Monkey study reveals clues for HIV eradication. Story
Pharma Manufacturing News
> Report: Indian government to take legal action over drug quality paper. Item
> Apotex tries to 'set the record straight' after Health Canada quarantine request. More
> FDA warns of contaminated Chinese meds after toddler suffers lead poisoning. Article
> Strides and Shasun plan merger to create big, 'de-risking' production network. Story
> Credit Suisse: FDA 483 unlikely to lead to import alert for Sun. Report